Kalaris TherapeuticsKLRS
13F holders, Q2 2025 (June 30)At the end of Q2 2025, 30 institutions reported holding Kalaris Therapeutics Inc. (KLRS) in their 13F filings, down 2 from Q1 2025. 4 opened new positions and 6 sold out. The largest holders were Samsara Biocapital, LLC ($30.6M), Tang Capital Management LLC ($963K) and Octagon Capital Advisors LP ($961K). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Kalaris Therapeutics Inc.
- CUSIP
- 482929106
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 4 | $72K |
| Exits | 6 | $1.9M |
All 13F filers, Q1 2025 → Q2 2025: 264,910 shares bought and 776,908 shares sold, net −511,998 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 30 holders
| Samsara Biocapital, LLC | 6.25% | No change | 11,448,081 | $30.6M |
| Tang Capital Management LLC | 0.05% | Add +16.7% | 360,859 | $963K |
| Octagon Capital Advisors LP | 0.21% | Reduce -25.2% | 360,000 | $961K |
| Gilead Sciences, Inc. | 0.07% | Reduce -56.1% | 317,789 | $848K |
| Siren, L.L.C. | 0.04% | No change | 282,586 | $755K |
| Vanguard Group Inc. | 0.00% | Add +12.8% | 129,839 | $347K |
| Renaissance Technologies | 0.00% | Add +402.6% | 96,751 | $258K |
| Redmile Group, LLC | 0.02% | No change | 82,955 | $221K |
| Squarepoint Ops LLC | 0.00% | Add +305.1% | 59,095 | $158K |
| Millennium Management | 0.00% | Add +226.2% | 54,092 | $144K |
| BlackRock, Inc. | 0.00% | Add +38.7% | 38,156 | $102K |
| Geode Capital Management, LLC | 0.00% | Reduce -4.9% | 25,476 | $68K |
| XTX Topco Ltd | 0.00% | New | 24,234 | $65K |
| Two Sigma Advisers, LP | 0.00% | Reduce -6.0% | 20,281 | $54K |
| RBF Capital, LLC | 0.00% | No change | 17,391 | $46K |
| Marshall Wace, LLP | 0.00% | No change | 14,115 | $38K |
| State Street Corp. | 0.00% | No change | 10,710 | $29K |
| FMR LLC | 0.00% | No change | 7,806 | $21K |
| UBS Group AG | 0.00% | Reduce -55.6% | 4,116 | $11K |
| Raymond James Financial Inc. | 0.00% | New | 2,629 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +50.1% | 2,153 | $6K |
| Morgan Stanley | 0.00% | Add +51.5% | 1,964 | $5K |
| Federated Hermes, Inc. | 0.00% | No change | 634 | $2K |
| Bank of America Corp. | 0.00% | Reduce -95.0% | 273 | $729 |
| BNP Paribas Financial Markets | 0.00% | Add +11.0% | 141 | $376 |
| JPMorgan Chase & Co. | 0.00% | Reduce -83.0% | 50 | $134 |
| Parallel Advisors, LLC | 0.00% | No change | 49 | $131 |
| Farther Finance Advisors, LLC | 0.00% | No change | 33 | $88 |
| SBI Securities Co., Ltd. | 0.00% | New | 10 | $27 |
| Royal Bank of Canada | 0.00% | New | 85 | $0 |
"% of holder's portfolio" is KLRS's weight in each manager's 13F, not the share of Kalaris Therapeutics Inc. the manager owns.